Scorpius Holdings AI Stock Analysis
Want to see SCPX full AI Analyst Report?
Scorpius Holdings (SCPX) AI Stock Analysis
Scorpius Holdings
(Other OTC:SCPX)
The score is held down primarily by weak financial performance (declining revenue, persistent losses, negative free cash flow, and high leverage). Technicals also skew bearish with price below key moving averages and negative MACD. Valuation provides limited support because a negative P/E reflects ongoing losses and there is no dividend yield data.
Scorpius Holdings (SCPX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $12.23K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- -7.26
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 91
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Scorpius Holdings Business Overview & Revenue Model
Company Description
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and sta...
How the Company Makes Money
Scorpius Holdings generates revenue through multiple streams, primarily from its strategic investments in various sectors. The company earns income by acquiring stakes in high-potential startups and established businesses, benefiting from capital app...
Scorpius Holdings Financial Statement Overview
Summary
Income statement and cash flow are weak: revenue declined 10.75% (2023 to 2024), net income remains negative with negative EBIT/EBITDA margins, and free cash flow is negative despite slight improvement. Balance sheet adds risk with high leverage (debt-to-equity 4.53), though stockholders’ equity remains positive.
Income Statement
30NegativeBalance Sheet
40NegativeCash Flow
35Negative| Breakdown | TTM | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.76M | 6.24M | 6.99M | 5.98M | 2.11M | 2.95M |
| Gross Profit | 367.51K | 3.05M | -2.22M | -420.02K | 1.42M | 2.95M |
| EBITDA | -23.22M | -26.22M | -33.99M | -38.26M | -34.94M | -24.59M |
| Net Income | -25.18M | -32.81M | -45.22M | -43.43M | -35.07M | -26.05M |
Balance Sheet | ||||||
| Total Assets | 20.77M | 39.18M | 51.04M | 104.40M | 120.96M | 124.19M |
| Cash, Cash Equivalents and Short-Term Investments | 600.79K | 2.38M | 2.39M | 39.03M | 96.38M | 111.77M |
| Total Debt | 18.12M | 28.55M | 14.04M | 9.30M | 1.93M | 1.85M |
| Total Liabilities | 27.75M | 37.50M | 22.74M | 31.96M | 8.93M | 8.70M |
| Stockholders Equity | -1.33T | 6.30M | 31.40M | 73.92M | 113.11M | 116.24M |
Cash Flow | ||||||
| Free Cash Flow | -9.75T | -26.88M | -33.52M | -25.82M | -40.03M | -22.36M |
| Operating Cash Flow | -6.78T | -26.01M | -31.53M | -5.70M | -38.13M | -22.02M |
| Investing Cash Flow | 77.44B | 1.21M | 32.24M | 10.99M | 9.77M | -95.42M |
| Financing Cash Flow | 6.19T | 25.64M | -8.95M | -4.91M | 25.49M | 119.33M |
Scorpius Holdings Risk Analysis
Scorpius Holdings disclosed 48 risk factors in its most recent earnings report. Scorpius Holdings reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksScorpius Holdings Peers Comparison
Overall Rating
SCPX39.7Underperform
SCNI39Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SCPX | Scorpius Holdings, Inc. | 0.01 | 0.00 | 0.00% | |
| SCNI | Scinai Immunotherapeutics Ltd. Sponsored Adr | 0.40 | -9.22 | -95.84% | |
| ADTX | Aditxt, Inc. | 0.04 | -915.80 | -100.00% | |
| CERO | Cero Therapeutics Holdings, Inc. | 0.01 | -0.06 | -86.30% | |
| PBM | Psyence Biomedical Ltd. | 3.15 | -14.92 | -82.59% | |
| CDT | Cdt Equity Inc. | 0.40 | -273949.63 | -100.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 29, 2026
